Introduction {#s1}
============

Serum markers are of considerable value for the clinical screening, diagnosis, and follow-up of cancers. An ideal marker should have high sensitivity and/or high specificity, in order to discriminate cancer patients from healthy subjects as well as from patients with benign tumors or unrelated conditions. Most currently used serum markers are hormones, glycoproteins, or other proteins overexpressed by cancer cells. These markers are usually not specific to a unique cancer type and sometimes lack sensitivity [@pone.0042470-Perkins1]. Several strategies have been recently proposed to identify new serum tumor markers [@pone.0042470-Alaiya1]. Differential proteomic analyses of serum specimens from cancer patients and healthy subjects are approaches of choice, but are hampered by the paucity of material in rare cancers as well as by the difficulty in detecting proteins that are expressed at low levels compared to abundant normal serum proteins. An alternative two-step approach involves the initial identification of proteins that are differentially expressed and/or secreted between normal and tumor cells, followed by the identification of these proteins in the serum of cancer patients. This approach ideally requires the isolation of primary tumor cells and corresponding normal cells. In this context, the use of relevant animal models of tumor development can provide essential starting materials for proteomic or genomic analysis, and lead to the identification of tumor-specific candidate proteins or genes whose expression can be then be investigated in human samples, as demonstrated in ovarian cancer [@pone.0042470-Wei1], [@pone.0042470-Pitteri1], [@pone.0042470-Mullany1].

The ovarian granulosa cell tumor (GCT) is the most prevalent of the sex cord/stromal subgroup of ovarian tumors in women, and is thought to represent up to 5% of all ovarian cancers. Over the past few years, our group has focused on the elucidation of the molecular etiology of human GCT, as well as on the creation of relevant animal GCT models. We found evidence that misregulation of both the WNT/CTNNB1 (ß-catenin) and PI3K/AKT signaling pathways occur in human GCT [@pone.0042470-Boerboom1], [@pone.0042470-Lague1]. Transgenic mice with constitutive activation of CTNNB1 in granulosa cells (GC, *Ctnnb1* ^tm1Mmt/+^;*Amhr2* ^tm3(cre)Bhr/+^) develop precancerous ovarian lesions that often progress into GCT later in life [@pone.0042470-Boerboom1]. The loss of the PI3K/AKT signaling antagonist gene *Pten* in GC rarely causes GCT, but concomitant activation of CTNNB1 and loss of *Pten* in the *Ctnnb1* ^tm1Mmt/+^;*Pten* ^tm1Hwu/tm1Hwu^;*Amhr2* ^tm3(cre)Bhr/+^ (CPA) model results in the development of aggressive, metastatic GCT with 100% penetrance [@pone.0042470-Lague1]. We have proposed that the CPA mouse is the best model currently available for the analysis of GCT biology as well as for preclinical animal studies aimed at developing novel therapeutic interventions and/or diagnostic tools.

We hypothesized that the CPA mouse model could be used for the identification of differentially expressed, GCT-associated proteins, and that these would translate to clinically useful novel serum diagnostic markers of the human disease. Here we present a differential secretome analysis comparing primary cultured GC from normal mice to GCT cells from CPA mice. This approach led to the identification of vasolin containing protein (VCP) as a potentially clinically relevant serum marker for human GCT, as well as for other forms of cancer.

Results {#s2}
=======

Identification of proteins secreted selectively in mouse GCT {#s2a}
------------------------------------------------------------

Proteomic profiling was used with the objective of identifying secreted proteins that could represent new serum diagnostic markers specific for GCT. Spent culture media were obtained from cultured GCT cells from CPA mice or from normal GC from eCG-stimulated ovaries. Proteins from the media were separated by SDS-PAGE and fourteen protein bands observed in GCT but not in GC medium were subjected to mass spectrometry analysis ([Figure 1](#pone-0042470-g001){ref-type="fig"}). This process identified a number of proteins that were more abundantly secreted or shed by GCT cells relative to normal GC ([Table 1](#pone-0042470-t001){ref-type="table"}). VCL, ENO1, several heat shock proteins (HSPA8/HSC70, the constitutive and inducible HSP90 alpha isoforms HSP90ab1 and HSP90aa1, and HSPA4), and VCP were the most consistently identified proteins from the GCT secretome.

![Differential protein expression in mouse granulosa cell and GCT cell culture media.\
Samples were separated by 10% SDS-PAGE followed by silver staining. Arrows indicate examples of proteins expressed selectively in the GCT cell culture media, along with approximate molecular weights. A total of 3 gels with different acrylamide contents were studied and 14 bands (with proteins from 12 to 116 KDa) were subjected to mass spectrometry analysis. Only one of the 3 gels is shown on the figure.](pone.0042470.g001){#pone-0042470-g001}

10.1371/journal.pone.0042470.t001

###### Mass spectrometry analysis of the secretome of mouse GCT from CPA transgenic mice.

![](pone.0042470.t001){#pone-0042470-t001-1}

  Protein Identification                              Protein Description                             Protein Score   Peptides
  ------------------------ ------------------------------------------------------------------------- --------------- ----------
  **IPI00405227**                                      **Vcl Vinculin**                                  **746**       **21**
  IPI00323357                                  Hspa8 Heat shock protein 8/Hsc70                            488           27
  **IPI00554929**           **Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class B member 1**       **468**       **13**
  **IPI00622235**                           **Vcp Valosin containing protein/p97**                       **372**       **12**
  IPI00462072                                   Eno1 Enolase 1 alpha non-neuron                            349           9
  **IPI00330804**           **Hsp90aa1 Heat shock protein 90, alpha (cytosolic), class A member 1**      **346**       **10**
  IPI00110827                                 Acta1 Actin alpha 1 skeletal muscle                          228           9
  IPI00124707                                      Fstl1 Follistatin-like 1                                228           5
  IPI00117312                      Got2 Glutamate oxaloacetate transaminase 2, mitochondrial               224           4
  **IPI00331556**                               **Hspa4 Heat shock protein 4**                           **201**       **5**
  IPI00466069                           Eef2 Eukaryotic translation elongation factor 2                    178           5
  IPI00135231                          Idh1 Isocitrate dehydrogenase 1 (NADP+), soluble                    171           4
  IPI00223231                               Qsox1 quiescin Q6 sulfhydryl oxidase 1                         157           4
  **IPI00126343**                    **Sparc Secreted acidic cysteine rich glycoprotein**                **132**       **4**
  IPI00313900                                             Lum Lumican                                      119           3
  **IPI00113517**                                    **Ctsb Cathepsin B**                                **113**       **3**
  IPI00133208                                Hspa1a Heat shock protein 1A/Hsp70-3                          106           3
  IPI00221402                               Aldoa Aldolase A, fructose-bisphosphate                        105           7
  IPI00228548                                     Eno3 Enolase 3 beta muscle                               101           3
  **IPI00124441**                              **Wif1 Wnt inhibitory factor 1**                          **82**        **2**
  **IPI00331286**                                **B2m beta-2-microglobulin**                            **79**        **3**
  **IPI00113863**                      **Timp2 Tissue inhibitor of metalloproteinase 2**                 **79**        **2**
  IPI00313296                              Rnh1 Ribonuclease/angiogenin inhibitor 1                        78            2
  IPI00762198                              Hbb-b1 Hemoglobin, beta adult major chain                       66            2
  IPI00109061                                       Tubb2b Tubulin beta-2B                                 63            2
  IPI00109073                                        Tubb4 Tubulin beta-4                                  63            2
  IPI00131547                Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1          55            2
  IPI00130391                                      Prss1 Protease, serine, 1                               54            2
  IPI00407502                             C1r Complement C1r-A subcomponent precursor                      50            2
  IPI00114209                                   Glud1 Glutamate dehydrogenase 1                            49            3
  IPI00127407                      Plod1 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1                43            2
  IPI00119809                  Lgals3bp Lectin, galactoside-binding, soluble, 3 binding protein            39            2
  IPI00122528                            Tgfbi Transforming growth factor-beta-induced                     31            2

Protein identification (International Protein Index identifier) and protein description are given along with the overall score and the number of peptides identified by mass spectrometry as described in Materials & Methods. Proteins in bold were studied further.

VCP is a serum marker for GCT and other cancer types {#s2b}
----------------------------------------------------

We next investigated whether the proteins secreted by GCT cells from CPA mice could serve as serum markers in human GCT patients. Human homologs of nine proteins identified in the secretome analyses (B2M, CTSB, HSPA4/HSP70, HSP90, SPARC, TIMP-2, VCP, VCL, and WIF-1) were selected for further study based on known gene functions and antibody availability. Serum samples were obtained from healthy volunteers and from patients with GCT prior to treatment. No significant differences in the levels of B2M, CTSB, HSP90, SPARC, TIMP-2, VCL or WIF-1 were observed by immunoblot analyses in the serum of GCT patients compared to healthy subjects (data not shown). Marginally increased levels of HSP4A were observed in the serum of some GCT patients compared to normal subjects, however the differences were not statically significant, and deemed unlikely to be clinically useful ([Figure 2A](#pone-0042470-g002){ref-type="fig"}). VCP levels were low in immunoblot analyses of serum samples from healthy subjects, but were significantly increased in the majority of serum samples from GCT patients (*P*\<0.05). With a reference value for VCP levels set at the mean of immunoblot band intensity values of the healthy controls plus twice the standard deviation, we observed that 8 out of 9 women with GCT displayed increased serum VCP levels ([Figure 2B](#pone-0042470-g002){ref-type="fig"}, [Table 2](#pone-0042470-t002){ref-type="table"}). To determine the specificity of VCP as a tumor marker for GCT, serum VCP levels were assessed in patients with ovarian carcinomas, as well as in small cohorts of patients with major non-ovarian cancers of known histology and grade ([Table 3](#pone-0042470-t003){ref-type="table"}). Surprisingly, elevated serum VCP levels were detected in clinically significant proportions of patients with ovarian carcinoma (8 of 8), breast cancer (5 of 12), colon cancer (7 of 12), pancreatic cancer (8 of 12) or non-Hodgkin\'s lymphoma (5 of 12) ([Figure 2B](#pone-0042470-g002){ref-type="fig"} and [Table 3](#pone-0042470-t003){ref-type="table"}). However, serum VCP levels were not meaningfully increased in patients with lung or prostate cancer.

![Serum levels of HSPA4 and VCP in healthy volunteers and in cancer patients.\
(A) HSPA4 levels in the serum of women with GCT or ovarian carcinoma. Equal amounts of serum protein were separated by SDS-PAGE and were subjected to immunoblot analysis for HSPA4 levels (representative blots are shown in the top panel, each lane represents a single donor). Densitometry analyses of signals obtained with the HSPA4 immunoblot analyses are reported in a graph in which each dot represents a single donor (bottom, horizontal bar = mean). No significant difference in HSPA4 levels was detected among groups by one-way ANOVA. (B) VCP levels are increased in the serum of cancer patients. Sera were analyzed as in (A) for the presence of VCP in patients with breast, colon, lung, pancreatic or prostate cancer, ovarian carcinoma, GCT, or non-Hodgkin\'s (NH) lymphoma. Statistically significant differences (*P*\<0.05) were detected between the control (normal) and GCT and colon cancer groups.](pone.0042470.g002){#pone-0042470-g002}

10.1371/journal.pone.0042470.t002

###### Serum levels of GCT markers in healthy women or in women with GCT.

![](pone.0042470.t002){#pone-0042470-t002-2}

  Group          Diagnosis        Menopausal status   INHA (ng/L)   INHB (ng/L)    CA-125 (U/ml)   VCP (arbitary units)
  --------- -------------------- ------------------- ------------- -------------- --------------- ----------------------
  control                               Post              NE           \<20.0            6                 110
  control                                Pre              NE           \<20.0            6                  46
  control                               Post              NE           \<20.0            6                 121
  control                               Post              NE          **24.7**           9                  0
  control                                Pre              NE           \<20.0           20                 241
  control                               Post              NE           \<20.0            7                  95
  control                               Post              NE           \<20.0           14                 117
  GCT            Adult GCT               Pre             \<13         **26.7**          NE               **1010**
  GCT            Adult GCT               Pre            **92**      **\>1136.0**        NE               **921**
  GCT        Adult GCT: Relapse         Post             \<13         **63.8**          NE               **1110**
  GCT            Adult GCT               Pre             \<13          \<20.0           NE               **1478**
  GCT            Adult GCT               Pre           **28.1**       **59.7**        **57**             **2212**
  GCT            Adult GCT              Post           **213.5**    **\>1136.0**      **231**            **1357**
  GCT            Adult GCT               Pre           **145.1**    **\>1136.0**      **120**            **964**
  GCT            Adult GCT               Pre           **21.1**        \<20.0           31               **308**
  GCT            Adult GCT              Post             \<13         **391**           NE                  83

Measurements that exceeded the normal reference range are indicated in bold. For inhibin A and B (INHA and INHB), values beneath the detection thresholds by ELISA were defined as normal. For VCP, the reference value was set as the mean of healthy control band intensity in immunoblot analyses+2SD (253 arbitrary units). Note that serum inhibin usually becomes undetectable after menopause in healthy women. Interpretation of premenopausal inhibin values can be difficult due to their secretion both by growing ovarian follicles and by GCTs. NE: not evaluated.

10.1371/journal.pone.0042470.t003

###### Tumor clinical features and VCP serum level in tested cancer patients.

![](pone.0042470.t003){#pone-0042470-t003-3}

                           Sample Number                        Histology                        Grade/Differentiation   VCP levels
  ----------------------- --------------- ----------------------------------------------------- ----------------------- -------------
  **Healthy donor**                                                                                                     
                                 1                                                                                          110.0
                                 2                                                                                          46.0
                                 3                                                                                          121.0
                                 4                                                                                           0.0
                                 5                                                                                          240.9
                                 6                                                                                          94.8
                                 7                                                                                          116.6
  **GCT**                                                                                                               
                                AM3                             Adult GCT                                 IA             **1010.4**
                                AM4                             Adult GCT                                 IA              **921.1**
                                AM5                        Adult GCT: Relapse                              X             **1109.6**
                                AM6                             Adult GCT                                 IA             **1478.0**
                                AM7                             Adult GCT                                IIIC            **2212.0**
                                AM8                             Adult GCT                                 IA             **1357.0**
                                AM9                             Adult GCT                                 IA              **964.0**
                               AM10                             Adult GCT                                 IC              **308.0**
                               AM11                             Adult GCT                                IIIc               83.0
  **ovarian cancer**                                                                                                    
                               AM12                         CL adenocarcinoma                             IC              **362.0**
                               AM13                         CL adenocarcinoma                             IIB             **266.0**
                               AM14                         EM adenocarcinoma                              I             **2069.0**
                               AM15                         EM adenocarcinoma                            IIIC            **1048.0**
                               AM16                    mucinous cystadenocarcinoma                        IA              **261.6**
                               AM17                    mucinous cystadenocarcinoma                       IIIC             **618.0**
                               AM18                     serous cystadenocarcinoma                        IIIC            **1046.4**
                               AM19                     serous cystadenocarcinoma                         III            **1836.7**
  **breast cancer**                                                                                                     
                             B00404105                    invasive mammary NOS                            III               121.8
                             B00405105                    invasive mammary NOS                             I              **708.8**
                             B00515113                    invasive mammary NOS                            III             **394.8**
                             B00516111                    invasive mammary NOS                            II              **343.9**
                             B00596105                    invasive mammary NOS                            II                126.7
                             B00649114                    invasive mammary NOS                            II                237.6
                             F00020105                             IDC                                     I                65.2
                             F00048105                             IDC                                    II                72.3
                             F00049105                             IDC                                    III            **1060.0**
                             F00116105                             IDC                                    II                30.9
                             F00117105                             IDC                                    III             **351.1**
                             F00372103                             IDC                                    II                25.4
  **colon cancer**                                                                                                      
                             B00266111                       Adenocarcinoma                               II             **2452.8**
                             B00279112                       Adenocarcinoma                               II             **2510.2**
                             B00443114                       Adenocarcinoma                               II                 8.1
                             B00457113                       Adenocarcinoma                               II                 2.6
                             B00502102                       Adenocarcinoma                               IV                11.3
                             B00530114                       Adenocarcinoma                               II                31.8
                             B00674115                       Adenocarcinoma                               II             **1157.1**
                             B00703104                       Adenocarcinoma                               IV             **1513.5**
                             B00728115                       Adenocarcinoma                               IV                44.6
                             B01057112                       Adenocarcinoma                               IV             **1595.2**
                             B01157113                       Adenocarcinoma                               IV             **2120.2**
                             B01595113                       Adenocarcinoma                               IV              **498.3**
  **pancreatic cancer**                                                                                                 
                             A01411102               invasive ductal adenocarcinoma                       III               4.23
                             B00537112                       Adenocarcinoma                               III                 0
                             B00627112                       Adenocarcinoma                                X             **367.56**
                             B02973106                 Ductal adenocarcinoma, NOS                         II              **277.7**
                             D00086102                    ductal adenocarcinoma                           II             **756.32**
                             D00205104                       adenocarcinoma                               III            **1445.88**
                             D00408101                       adenocarcinoma                                X             **1268.59**
                             D00544102                       adenocarcinoma                               II             **372.54**
                             D01000101                      ductal carcinoma                              II             **779.26**
                             D01013101                      ductal carcinoma                              II             **761.58**
                             E01584101               invasive ductal adenocarcinoma                       II                72.89
                             F00302101                    ductal adenocarcinoma                           II                77.15
  **lung cancer**                                                                                                       
                             A00195101                       adenocarcinoma                               III               41.58
                             A00242102                LC undifferentiated carcinoma                        X                158.4
                             A00327102                       adenocarcinoma                                I                195.6
                             A00392101                       adenocarcinoma                                I               148.76
                             A00404102                     squamous carcinoma                             II                86.63
                             A00699101                       adenocarcinoma                                X             **272.46**
                             A00710101                       adenocarcinoma                               III              168.24
                             A00728102                       adenocarcinoma                                I               208.09
                             A01015104                LC undifferentiated carcinoma                        X                14.4
                             A01341101                     squamous carcinoma                             III               82.37
                             A01429101                     squamous carcinoma                             II             **351.27**
                             A02117112                     squamous carcinoma                             II               119.04
  **prostate cancer**                                                                                                   
                             A01598101                       adenocarcinoma                               T3b               89.97
                             A01738101                       adenocarcinoma                               T3b               44.24
                             B02131103                       adenocarcinoma                               T3b               42.92
                             B02408102                       adenocarcinoma                               T2c              **298**
                             B02409102                       adenocarcinoma                               T2c              114.31
                             B02469101                       adenocarcinoma                             T3,NOS              11.07
                             B02682102                       adenocarcinoma                               T2c              147.48
                             B02683103                       adenocarcinoma                               T2c              124.46
                             B02704103                       adenocarcinoma                               T2c              135.62
                             B02725101                       adenocarcinoma                               T2c               3.72
                             B03083102                       adenocarcinoma                               T3b               37.73
                             F00339102                       adenocarcinoma                               T3a               34.9
  **NHDG**                                                                                                              
                             A00730101     mixed; follicular and diffuse large B cell lymphoma            IE                  0
                             A01749102                diffuse large B cell lymphoma                        X                  0
                             B01423113                  small bowel lymphoma NOS                          IVE            **2753.45**
                             B01563111                   testicular lymphoma NOS                          IV               181.93
                             B01824113                     follicular lymphoma                            IV                  0
                             B02332112     mixed; follicular and diffuse large B cell lymphoma            III               252.9
                             B02337111     mixed; follicular and diffuse large B cell lymphoma            IV                  0
                             D00776101     mixed; follicular and diffuse large B cell lymphoma             I             **1203.38**
                             D02063102                     follicular lymphoma                             X             **2911.73**
                             D02342103                   marginal zone lymphoma                            X             **447.32**
                             D02482102                             NA                                      X             **1136.11**
                             E00273103                     follicular lymphoma                            IV                  0

For VCP, the reference value was set as the mean of healthy control band intensity in immunoblot analyses+2SD (253 arbitrary units). Positive VCP values are indicated in bold. X: unknown grade/differentiation, CL: clear cell, EM: endometroid, NOS: not otherwise specified, IDC: invasive ductal carcinoma, LC: large cell, NHDG: non-Hodgkin\'s lymphoma, NA: not available.

Specificity and sensitivity of VCP relative to widely-used serum diagnostic markers {#s2c}
-----------------------------------------------------------------------------------

We next compared the relevancy of VCP to that of other commonly-used serum diagnostic markers for various cancer types. Presently, the most useful serum markers for GCT in postmenopausal women are inhibin A and inhibin B [@pone.0042470-Geerts1]. In our cohort, inhibin A and inhibin B serum levels were increased in 5 out 9 and 7 out of 9 of patients with GCT ([Table 2](#pone-0042470-t002){ref-type="table"}), respectively. There was no clear correlation between preoperative levels of inhibin A, inhibin B and VCP in GCT patients, nevertheless one patient had undetectable serum levels of inhibin A and inhibin B but highly increased levels of VCP ([Table 2](#pone-0042470-t002){ref-type="table"}). The sensitivity of VCP therefore appears to compare favorably to that of the inhibins, and VCP could serve to identify rare inhibin-negative GCT patients. Serum CA125 is increased in approximately 50% of women with early ovarian carcinoma and in over 80% of women with advanced disease and is useful for monitoring therapy [@pone.0042470-Carlson1]. In our small ovarian carcinoma cohort, 4 of 8 patients tested positive for CA125, whereas VCP measurement detected cancer in all patients, including those negative for CA125 ([Figure 3](#pone-0042470-g003){ref-type="fig"}). CEA is the most widely used serum tumor marker for colon cancer. Serum CEA is elevated in less than 25% of early stage colon cancer and 75% of late-stage cancer and is useful for determining prognosis, monitoring therapy and surveillance [@pone.0042470-Sturgeon1]. In the 12 colon cancer patients that we tested, 5 were positive for CEA. VCP measurement detected cancer in all CEA-positive patients, in addition to two that were CEA-negative ([Figure 3](#pone-0042470-g003){ref-type="fig"}). CEA and CA15.3 are the most commonly used serum markers for breast cancer. Assessment of these markers is not recommended for prognosis but rather for postoperative follow-up as well as monitoring in advanced diseases [@pone.0042470-Sturgeon1]. In the 12-case cohort that we examined, 3 patients tested positive for either CEA or CA15.3, with the remainder negative for both. VCP levels were elevated in all three patients that were CEA- or CA15.3-positive, and also in three patients that were negative for both markers ([Figure 3](#pone-0042470-g003){ref-type="fig"}). Thus, VCP serum levels were significantly increased in the majority of the tested cancer patients, including in some otherwise negative for established serum tumor markers.

![Assessment of serum levels of VCP compared to serum tumor markers currently used for ovarian carcinoma, colon cancer, and breast cancer.\
Sera from patients were tested for VCP levels by immunoblot analyses and the dotted line shows VCP cutoff values established in healthy donors. In addition, sera were tested by ELISA for the presence (+) or absence (−) of increased levels of CA125 in ovarian carcinoma, CEA in colon cancer, or CEA and CA15.3 in breast cancer. The normal ranges of CA125, CEA, and CA15.3 are below 35 U/ml, 7 µg/l, and 29 kU/l, respectively.](pone.0042470.g003){#pone-0042470-g003}

Discussion {#s3}
==========

The VCP protein is a AAA+ ATPase associated with diverse cellular activities. VCP is necessary for the maintenance of cellular protein homeostasis and regulates the expression of proteins involved in many functions such as DNA replication, mitosis, protein degradation, endocytosis, membrane fusion, and organelle biogenesis. Specifically, VCP acts on ubiquitinated substrates molecules and regulates protein turnover by balancing the proteosomal degradation of soluble proteins or misfolded protein aggregates localized in the ER lumen or the cytosol. Depending on conformational recoverability of complexes with VCP and target protein substrates, VCP either promotes their degradation, segregates them from large protein complexes, or modulates their ubiquitination by competing ubiquitin conjugation and deconjugation machineries (reviewed in [@pone.0042470-Halawani1]). VCP associates with numerous ubiquinated substrates, and the functions of VCP in different cell types relates in part to the specific tissue expression of substrates and co-factors. In neurons and muscle cells, VCP interaction with NF-1, UNC45b, and caveolin-3 regulates synaptogenesis and myofibrogenesis (reviewed in [@pone.0042470-Weihl1]). Some autosomal dominant mutations in the VCP gene cause inclusion body myopathy with Paget disease of the bone and frontotemporal dementia (IBMPFD) which is a rare, late age--onset inherited degenerative disorder that can affect the muscles, bones and brain [@pone.0042470-Watts1]. In addition to essential functions in homeostasis, VCP was shown to regulate the half-life and levels of several proteins with cancer-modulating functions. For instance, VCP in cooperation with several ubiquitin ligases regulates the turn-over of IkappaB [@pone.0042470-Dai1], HIF-1 [@pone.0042470-Alexandru1], p53 [@pone.0042470-Valle1], or ErbB3 [@pone.0042470-Fry1]. Mutations and/or misregulation of VCP functions in cancer cells are still not well characterized, as are their possible causative effects in tumorigenesis. Nevertheless, overexpression of VCP has recently been evidenced *in situ* in a wide array of human cancer types, and analyses of large patient cohorts demonstrated significantly increased expression levels of VCP by tumor cells often correlate with disease progression [@pone.0042470-Tsujimoto1], [@pone.0042470-Yamamoto1], [@pone.0042470-Yamamoto2], [@pone.0042470-Yamamoto3], [@pone.0042470-Yamamoto4], [@pone.0042470-Yamamoto5], [@pone.0042470-Yamamoto6], [@pone.0042470-Yamamoto7]. However, the present report is the first to identify increased VCP levels in the serum of cancer patients.

Taken together, our results indicate that VCP represents a highly sensitive, potentially clinically useful serum tumor marker for a variety of human cancers. Although its lack of specificity for a single cancer type suggests that it is unlikely that VCP serum measurement could be used as a screening tool, its sensitivity equivalent or superior to many commonly used markers indicates that it could be used in applications such as monitoring treatment efficacy, or monitoring for disease recurrence. Additionally, VCP could be used for diagnosis in conjunction with more cancer type-specific markers to increase the overall sensitivity of the assay. Screening of much larger cohorts will be required to determine the sensitivity of serum VCP measurement for the detection of different stages of cancer progression, and of different cancer subtypes. Furthermore, the specificity of VCP with regards to the detection of neoplastic vs non-neoplastic disease will need to be assessed before its usefulness as a tumor marker can be definitively established. As immunoblotting is limited both in terms of quantitativeness and technical practicality, large-scale screening will require the development of a high-throughput ELISA assay for VCP.

In summary, our results demonstrate that proteomic profiling of tumor secretomes from clinically relevant mouse models can lead to the identification of candidate circulating proteins associated with tumorigenesis in humans. We report that VCP is overexpressed in the serum of cancer patients, and that it may represent a new clinically useful marker for cancer detection.

Materials and Methods {#s4}
=====================

Mice {#s4a}
----

*Ctnnb1* ^tm1Mmt/+^;*Pten* ^tm1Hwu/tm1Hwu^;*Amhr2* ^tm3(cre)Bhr/+^ (CPA) transgenic mice were generated as previously described [@pone.0042470-Lague1] and maintained on a C57BL/6 genetic background. In these mice, constitutive activation of CTNNB1 signaling is due to the deletion of the third exon of *Ctnnb1*, resulting in the production of a dominant-stable CTNNB1 mutant protein that lacks the phosphorylation sites required for its proteosomal degradation [@pone.0042470-Boerboom1]. CPA mice develop GCT perinatally and die before 8 weeks of age [@pone.0042470-Lague1]. All animal procedures were approved by the Institutional Animal Care and Use Committee and were conform to the USPHS Policy on Humane Care and Use of Laboratory Animals.

Cell culture {#s4b}
------------

Normal GC were isolated using the method described by Zeleznik et al. [@pone.0042470-Zeleznik1]. Briefly, immature (23--26 day-old) C57BL/6 mice were injected I.P. with 5 IU equine chorionic gonadotropin (eCG, Folligon, Intervet, Schering-Plough) to induce follicular growth. Forty-eight hours later, animals were sacrificed and the ovaries punctured with a 25-gauge needle to free GCs into the medium (0.9% NaCl). The cell suspension was centrifuged at 1,000 *g* for 5 min and resuspended GC were plated into 24 well plates at 70% confluency in DMEM/F12 medium (Sigma Aldrich) supplemented with 5% FBS (Invitrogen), penicillin and streptomycin (P/S). GCT from 21 to 25 day-old CPA mice were excised, minced with a size 10 scalpel blade and digested for 2 h with 0.1% collagenase from *Clostridium histolyticum* (Sigma) in serum-free DMEM with P/S. Cells were then centrifuged at 1,000 *g* for 10 min and resuspended in DMEM supplemented with 10% FBS and P/S prior to plating into 100 mm cell culture dishes (25×10^6^ cells/dish).

Differential secretome analyses {#s4c}
-------------------------------

Twenty-four hours after plating, cultured GC and GCT cells were washed with HBSS (Invitrogen) and incubated for 24 h in serum-free DMEM. Supernatants were collected and concentrated 80-fold using Amicon Ultra-4 centrifugal filter units (Millipore) with a 3 kDa molecular weight cut-off. Protein concentrations were quantified using the method of Bradford (Bio-Rad protein assay) and 4--6 µg protein samples were separated by SDS-PAGE. Following silver staining, proteins bands found in GCT but not in GC samples (n = 14) were excised from the gel. The gel slices were destained with 50% methanol then reduced in 10 mM DTT for 1 hour at 56°C and alkylated in 55 mM chloroacetamide for one hour at room temperature. After washing in 50 mM ammonium bicarbonate, the gel pieces were shrunk in 100% acetonitrile (ACN). Digestion was performed using trypsin in 50 mM ammonium bicarbonate for 8 hours at 37°C. The peptides were finally extracted in 90% ACN/0.5 M urea and dried in a speed vacuum. Samples were resolubilized in 5% ACN with 2% formic acid (FA) and separated on a homemade C~18~ column (150 µm×10 cm) using an Eksigent nanoLC-2D system. A 56-min gradient from 5--60% ACN (0.2% FA) was used to elute peptides from a homemade reversed-phase column (150 µm i.d. ×100 mm) with a flow rate set at 600 nanoliter/min. The column was directly connected to a nanoprobe interfaced with an LTQ-Orbitrap Velos mass spectrometer (Thermo-Fisher). Each full MS spectrum was followed by twelve MS/MS spectra (thirteen scan events), where the twelve most abundant multiply-charged ions were selected for MS/MS sequencing. Tandem MS experiments were performed using collision-induced dissociation in the linear ion trap. The data were processed using the 2.1 Mascot (Matrix Science) search engine with tolerance parameters set to 15 ppm and 0.5 Da for the precursor and the fragment ions respectively. The selected variable modifications were carbamidomethyl (C), deamidation (NQ), oxidation (M) and phosphorylation (STY). The selected database was human IPI database v.3.54 with 150858 sequences.

Serum samples {#s4d}
-------------

Serum samples from patients with breast, colon, lung, pancreatic or prostate cancer, or non-Hodgkin\'s lymphoma (n = 12 for each cancer type) were obtained from the Ontario Tumour Bank. Serum samples from healthy volunteers (n = 7) and patients with GCT (n = 9) or ovarian carcinoma (n = 8; 2 clear cell, 2 serous, 2 mucinous and 2 endometrioid ovarian cancers) were obtained from the Réseau de recherche du cancer du Fonds de recherche Québec - Santé. Procedures were approved by the FRQS-RRCancer Research Committee and the Ontario Cancer Research Ethics Board, as well as the Comité d\'éthique de la recherche sur les sujets humains of the Centre hospitalier de l\'Université de Montréal. Inhibin A and inhibin B levels were determined by ELISA at the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core. Values for inhibin A and B beneath the detection threshold (13 ng/l and 20 ng/l, respectively) were defined as normal. CA15.3 and CEA levels were determined by les Laboratoires du Centre Hospitalier de l\'Université de Montréal. Values below 7 µg/l and 29 kU/l for CEA and CA 15.3, respectively, were considered normal. CA125 levels were determined using a commercially available ELISA assay kit and levels were considered as normal when below 35 U/ml (Abnova).

Immunoblot analyses {#s4e}
-------------------

Serum samples (4 µl i.e. approximately 200 µg) were separated by SDS-PAGE on 10% acrylamide gels. The gels were transferred to polyvinylidene fluoride membranes (GE Amersham/VWR). Immunodetection was performed with HSPA4- or VCP-specific antibodies (clones ab75977 or ab11433 respectively, Abcam) and horseradish peroxidase-conjugated secondary antibodies (GE Amersham/VWR) and revealed using ECL Detection Reagents (GE Amersham/VWR). Quantification of the protein bands was performed by densitometry analyses using a Kodak Image Station 440CF and Kodak 1D v.3.6.5 software (Eastman Kodak, Rochester, NY). In order to normalize VCP or HSPA4 protein levels between immunoblots, each gel contained two or three common serum samples as references. The reference value for VCP was set as the mean of healthy control band intensities in immunoblot analyses+2SD.

Statistical analyses {#s4f}
--------------------

One-way ANOVA with Dunnett\'s post-test was used to compare VCP levels in healthy women and cancer patients.
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